The promise of precision medicine and the arrival of personalized therapy has transformed lung cancer care with a number of genetic alterations that have come to fruition or are quickly rising with promising trial results, including EGFR, ALK, ROS1, MET, RET, NTRK, BRAF, KRAS, and immunotherapies (Table 1). The gene discussed is EGFR; the disease is lung cancer.